Caedo Oncology

Executive Summary

Caedo Oncology AS is a privately held Norwegian biotechnology company headquartered in Oslo, founded in 2018. The company specializes in developing novel monoclonal antibody-based therapies, leveraging innovative strategies to target cancer. While still in early stages with no disclosed pipeline or funding details, Caedo Oncology's focus on antibody biologics positions it within a competitive but rapidly evolving field. The company's research appears to be at a preclinical or early clinical stage, typical for a private biotech of its size and age. Given the lack of public information on specific programs, Caedo Oncology represents an early-stage investment opportunity with potential upside from future data readouts or partnerships. Caedo Oncology's progress will depend on advancing its proprietary antibody platforms into validated lead candidates. The company's ability to secure partnerships or additional funding will be critical for moving toward clinical trials. While the biotech sector in Norway is growing, Caedo faces significant competition from larger antibody developers. The company's success hinges on demonstrating differentiation, such as novel targets or enhanced efficacy/ safety profiles. Investors should monitor for any announcements regarding lead program nominations, preclinical data, or strategic alliances. The current conviction is moderate due to limited publicly available data.

Upcoming Catalysts (preview)

• H2 2026Lead Program Preclinical Data Release30% success
• 2027Strategic Partnership or Licensing Deal20% success
• 2026Series A or Series B Funding Round40% success